PTPRC and neoplasm: Our CHCs are different from reported hybrid cells in blood 55, 56 in two aspects: our tumor cells expressed positivity to the pan-leukocyte antigen CD45 and either one of the combinations; CTC epithelial marker E-cadherin or simultaneously, both E-cadherin and the CTC mesenchymal marker vimentin.